Avestar Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Avestar Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-86	Closed	-$10K	–	914
2018 Q4	$10K	Sell	86 -3	-3%	-$445	0.01%	440
2018 Q3	$14K	Sell	89 -7	-7%	-$1.2K	0.01%	412
2018 Q2	$15K	Buy	96 +86	+860%	+$14.1K	0.01%	398
2018 Q1	$1K	Buy	10 +1	+11%	+$147	﹤0.01%	731
2017 Q4	$1K	Buy	+9	New	+$1.25K	﹤0.01%	702

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Avestar Capital's JAZZ Position: Q1 2019 in Review

Avestar Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2019, closing a stake of 86 shares — an estimated $10K sold.

Avestar Capital first reported a position in JAZZ in Q4 2017 and held it in 5 quarters. The position peaked at $15K in Q2 2018. 427 funds tracked by Wall St. Rank hold JAZZ as of Q1 2019.

Avestar Capital reported no remaining Jazz Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Avestar Capital sold 86 Jazz Pharmaceuticals shares in Q1 2019, an estimated $10K.
Avestar Capital first reported a position in Jazz Pharmaceuticals in Q4 2017 and held it in 5 quarters.
Avestar Capital's Jazz Pharmaceuticals position peaked at $15K in Q2 2018.
427 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2019.

Based on Avestar Capital's 13F filing for Q1 2019, filed 9 May 2019.